Jialal and Pahwa note the importance of daratumumab interference with monoclonal protein quantitation in multiple myeloma [1] . We agree that daratumumab may interfere with monoclonal protein quantitation. While the focus of our manuscript was to describe a method to reduce the risk of inaccurate response classification [i.e. very good partial response (VGPR) vs. complete response (CR)] [2], inaccurate quantitation due to positive interference by daratumumab could give the impression of resistance to therapy.
To the Editor, Jialal and Pahwa note the importance of daratumumab interference with monoclonal protein quantitation in multiple myeloma [1] . We agree that daratumumab may interfere with monoclonal protein quantitation. While the focus of our manuscript was to describe a method to reduce the risk of inaccurate response classification [i.e. very good partial response (VGPR) vs. complete response (CR)] [2] , inaccurate quantitation due to positive interference by daratumumab could give the impression of resistance to therapy.
One point of clarification is that the clinical consequences of the described bias are difficult to estimate. Statistical significance aside, the effect size of the bias appears to be largely below the reference change value (RCV) as determined from biological variation and imprecision data for monoclonal proteins [3, 4] . The estimated RCV for monoclonal proteins ranges from 27% to 56%. The reported median bias of 10% and the maximum observed bias of approximately 32% are thus largely within the combined biological variation and noise of monoclonal protein quantitation by serum protein electrophoresis (SPE; scanning densitometry). In the same line, imprecision of the SPE method may explain the reported interference of M-protein concentration in patients in which the M-protein does not co-migrate with daratumumab. Daratumumab consistently migrates as a sharp band at the same electrophoretic location, and interference on quantification with nonoverlapping M-proteins is therefore not expected. Further, it is unlikely that the daratumumab treatment course would change as a result of a ≤ 1 g/L positive bias; the maximum mean (± standard deviation) reported maximum concentration for daratumumab at the end of the initial weekly dosing schedule at a dose of 16 mg/kg is 915 (410) μg/mL [5] . We agree that further studies aimed at determining if there is a clinical impact are warranted.
With respect to the daratumumab immunofixation reflex assay (DIRA), this method is not intended to address the issue of quantitation, but rather to determine if the patient has achieved immunofixation-negative serologic CR or not. We only recommend selective use to differentiate response classification for several reasons: (1) there is a lack of available antisera available to most laboratories; (2) as Jialal and Pahwa state, there is an added expense and complexity in immunofixation interpretation; and (3) laboratories running SPE typically do not know if daratumumab is present in most routinely obtained SPE samples. Thus, DIRA is recommended in selected cases using experienced interpreters, where it is essential to accurately differentiate VGPR versus CR, for example, as part of a
